Details
Category: Volume 07 Issue 07 July 2019
Hits: 1130

Title: Pulmonary Mucormycosis in an Elderly Patient with multiple Comorbidities

Authors: Mukund K. Sasturkar, Sharad B. Biradar

 DOI: https://dx.doi.org/10.18535/jmscr/v7i7.75

Abstract

Pulmonary Mucormycosis, a rare opportunistic invasive pulmonary fungal infection.1 Mucormycosis is less common than other opportunistic fungal infections, such as aspergillus and candida infections, but mortality rate is much higher. We report a case of 79 year old male patient with multiple comorbidities who presented to Manik Hospital and Research Centre  with 1 month history of cough, fever and breathing difficulty and  diagnosed to have pulmonary mucormycosis and treated successfull

Keywords: Pulmonary mucormycosis with multiple comorbidities, diagnosis and treatment.

References

  1. Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, Huhndorf S, James T, Kirk PM, Lucking R, et al. A higher level of phylogenetic classification of fungi. Mycol Res. 2007;111:509-547. Doi: 10.1016/j.mycres.2007.03.004
  2. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemology and clinical manifestation of mucormycosis. Clin infect dis 2012;549 suppl 1):S23-S34
  3. Kauffman CA, Malani AN.  Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep 2007;9:435
  4. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, ChuJH, Kontoyiannis DP, Walsh TJ. Clin Infect Dis. 2005;41(5):634
  5. Mucormycosis of nose and paranasal sinuses. Ferguson BJ. Otolaryngol Clin North Am. 2000;33(2):349.
  6. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Curr Opin Infect Dis. 2004;17(6):517
  7. Li WF, He C, Liu XF,Wang SY,QuJL, Lin ZF. A diagnosis neglected for 6 years; Report of a misdiagnosed case of pulmonary mucormycosis and review of literature. Chin Med J (Engl) 2010;123: 2480-2482.
  8. Mold infections of central nervous system. McCarthy M, Rosengart A, S chuetz AN, Kontoyiannis DP, Walsh TJ. N Engl J Med. 2014 Jul;371(2):150-60.
  9. Wolf O, Gil Z, Leider-Trejo L, Khafif A, Biderman P, Fliss DM. Tracheal mucormycosis presented as intraluminal soft tissue mass. Head Neck. 2004;541-543.
  10. New agents in treatment of fungal infections: clinical efficacy and gaps in coverage. Spanakis EK, Aperis G, Mylonakis E. Clin Infect Dis. 2006;43(8):1060. Epub 2006 Sep 8.
  11. In vitro activities of posaconazole, itraconazole, voriconazole, amphoctericin B, and fluconazole against 37 clinical isolates of zygomycetes. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybil JR. Antimicrob Agents Chemother. 2002;46(5):1581.
  12. Mucormycoses. Farmakiotis D, Kontoyiannis DP. Infect Dis Clin North Am. 2016 Mar;30(1):143-63.
  13. Pulmonary mucormycosis: results of medical and surgical therapy. Tedder M, Spratt JA, Anstadl MP, Hegde SS, Tedder SD, Lowe JE. Ann Thorac Surg. 1994;57(4):1044.
  14. Broncovascular mucormycosis in the diabetic: an urgent surgical problem. Brown RB, Johnson JH, Kessinger JM, Sealy WC. Ann Thorac Surg. 1992;53(5):854

Corresponding Author

Sharad B. Biradar

Head of Department of Critical Care, Manik Hospital and Research Centre, Aurangabad, Maharashtra, India